Part 3 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue & Patient Care
AFPs don’t simply shift costs—they can also introduce delays, fragment patient support, and create hidden revenue loss that standard metrics often fail to capture.
Alternate Funding Programs (AFPs) are often evaluated through a financial lens. They reduce employer drug spend. They shift the cost away from the health plan. They appear, on the surface, to preserve patient access. But that view is incomplete.
Behind the scenes, AFPs introduce friction into the patient journey, disrupt continuity of care, and create financial dynamics that fundamentally alter how brands realize revenue. At the same time, many of these effects remain invisible to the systems manufacturers rely on to measure performance.
In Part 2, we examined how AFPs operate. Here, we focus on what they change—and why those changes are often difficult to see.
The Patient Experience: Disruption Beneath the Surface
AFPs do not eliminate access to therapy, but they can delay it, cause confusion, and disrupt care. The effects can include:
Delays at initiation
AFP enrollment introduces additional steps into an already complex specialty onboarding process. Patients may be required to complete new forms, respond to outreach from unfamiliar organizations, or navigate benefit changes that are not clearly explained.
These steps add time. For patients starting therapy for conditions such as rheumatoid arthritis, multiple sclerosis, or oncology indications, delays of several weeks can occur between prescription and treatment initiation. These delays are not always visible in standard metrics, but they carry clinical and emotional consequences.
Confusion about coverage
Patients are rarely given a clear explanation of AFP mechanics. When their expected pharmacy benefit no longer applies, many interpret the change as a loss of coverage.
They may contact their insurer, their provider, or their pharmacy seeking clarification—often receiving inconsistent answers. This creates uncertainty at a moment when patients are already managing a serious diagnosis.
In some cases, the complexity of the process leads patients to abandon therapy altogether.
Disrupted continuity of care
AFP programs frequently redirect patients to specific specialty pharmacies aligned with the program. This can break established connections between patients, providers, and manufacturer support programs.
Nursing support, refill reminders, adherence coaching, and pharmacist consultations may be lost or fragmented. Manufacturer hub programs, which are designed to provide continuity and visibility into the patient journey, are often bypassed entirely.
The result is a patient experience that appears functional—but is less stable, less supported, and more difficult to navigate.
The Economic Impact: Cost Without Visibility
While AFPs reshape the patient journey, they also reshape brand economics. The most direct impact is the shift from commercial revenue to free goods.
Free goods without commercial offset
Patients who would typically be covered under a commercial benefit are instead served through manufacturer funded programs. The manufacturer absorbs the full cost of therapy—drug, distribution, and support without receiving corresponding commercial revenue.
Unlike traditional participants in Patient Assistance Programs (PAPs), who are uninsured or underinsured, AFP-diverted patients are drawn from commercially insured populations. Their coverage has simply been engineered out of the pathway.
Gross-to-net erosion
This dynamic accelerates an already complex Gross-to-Net (GTN) challenge. Manufacturers incur the cost of free goods while also managing other forms of discounting—such as rebates, copay assistance, and distribution costs. In some AFP structures, copay assistance is provided early in the patient journey, before transitioning to free goods, thereby further increasing the financial burden.
The result is a revenue profile that is difficult to reconcile. Patient volume may appear stable or even increasing, while net revenue declines in ways that are not immediately explained.
A distorted commercial picture
AFP activity introduces a fundamental disconnect between patient counts and revenue realization. From a data perspective, patients may still appear as active users of a therapy. But from a financial perspective, they are not contributing commercial revenue. This creates a form of hidden leakage—one that can materially impact brand performance without being clearly attributed.
Why These Impacts Are Often Invisible
One of the most challenging aspects of AFPs is not just their impact but also how difficult they are to detect.
Fragmented data sources
The data required to identify AFP activity is distributed across multiple systems:
- Specialty pharmacy dispensing data
- PAP enrollment records
- Foundation assistance data
- PBM claims
No single source provides a complete view of the patient pathway.
The “normal fill” illusion
From the outside, AFP-diverted patients often look like typical commercial patients. Prescriptions are filled. Therapy continues. Adherence metrics may appear consistent. However, the financial context is missing. Without visibility into benefit design changes, PAP enrollment pathways, or foundation routing, these patients are indistinguishable from standard commercial fills in many reporting systems.
Misaligned incentives across the ecosystem
Participants in the AFP ecosystem—vendors, PBMs, specialty pharmacies—are not always positioned to surface AFP activity to manufacturers. In many cases, they are aligned with employer cost-containment goals.
As a result, even well intentioned stakeholders may not provide clear signals that a patient has been diverted.
A System-Level Impact
Taken together, these dynamics create a system-level effect. Patients experience delays, confusion, and fragmented support. Manufacturers absorb costs without corresponding revenue. Brand teams operate with incomplete visibility into both.
Individually, each of these effects may appear manageable. In aggregate, they represent a meaningful shift in how specialty therapies are accessed, funded, and measured.
Looking Ahead
Understanding the patient and economic impact of AFPs is a critical step—but it is only part of the picture. In the next blog, we will examine why AFP activity is so difficult to detect at scale and what manufacturers can do to build greater visibility and control.
